-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-014 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-014 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Type 2 Diabetes Drug Details: XW-014 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-014 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-014 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Obesity Drug Details: XW-014 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-004 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-004 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-004 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: XW-004 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: XW-014 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navitoclax Dihydrochloride in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navitoclax Dihydrochloride in Myelofibrosis Drug Details: Navitoclax (ABT-263, RG7433) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Encorafenib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Encorafenib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Encorafenib in Relapsed Multiple Myeloma Drug Details: Encorafenib (Braftovi) acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Non-Alcoholic Steatohepatitis (NASH) Drug Details: XW-003 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine in Parkinson's Disease report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1819479 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BI-1819479 in Idiopathic Pulmonary Fibrosis Drug Details:BI-1819479 is under development for the treatment of unspecified indication,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-004 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-004 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-004 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: XW-004 is under development...